|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | 0.00% |
|
0.00% | -99.00% |
| Market Cap | 6.24M 4.43M 3.89M 3.63M 3.33M 424M 6.39M 43.06M 16.84M 210M 16.62M 16.26M 725M | P/E 2022 |
-2.09x | P/E 2023 | -0.45x |
|---|---|---|---|---|---|
| Enterprise Value | 64.5M 45.77M 40.22M 37.54M 34.45M 4.38B 66.09M 445M 174M 2.17B 172M 168M 7.5B | EV / Sales 2022 |
3.37x | EV / Sales 2023 | 1.35x |
| Free-Float |
52.66% | Yield 2022 * |
-
| Yield 2023 | - |
| Current year | 0 |  | 0 |
| 1 year | 0 | | 0 |
| 3 years | 0 | | 0.4 |
| 5 years | 0 | | 0.84 |
| 10 years | 0 | | 1.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Tougas
DFI | Director of Finance/CFO | - | 2023-11-19 |
Nelly Komari
CTO | Chief Tech/Sci/R&D Officer | - | 2021-05-31 |
Frédéric Dumais
IRC | Investor Relations Contact | - | 2019-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Steven Saviuk
CHM | Chairman | 67 | 2024-08-05 |
Richard MacKay
CHM | Chairman | 91 | 2018-07-24 |
Marc Léger
BRD | Director/Board Member | 67 | 2022-04-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% | ||
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% | ||
| 11/11/24 | Other | Investor Relations Manager | 0 | 0% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 98 | |
| -0.87% | +4.04% | +58.60% | +163.92% | 1,079B | |
| -0.45% | +3.87% | +57.95% | +52.18% | 640B | |
| +0.04% | +3.95% | +37.69% | +74.54% | 465B | |
| -2.53% | +1.20% | +36.25% | +30.71% | 353B | |
| -1.72% | -0.11% | +34.20% | +40.02% | 301B | |
| -2.76% | +0.74% | +11.17% | +14.27% | 271B | |
| -2.03% | +3.72% | +2.22% | -39.17% | 228B | |
| -1.39% | +5.90% | +27.70% | +64.00% | 209B | |
| -1.18% | +1.83% | +16.20% | +72.69% | 165B | |
| Average | -1.66% | +4.35% | +31.33% | +52.57% | 370.97B | |
| Weighted average by Cap. | -1.96% | +4.86% | +41.22% | +77.67% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 27.74M 19.69M 17.3M 16.15M 14.82M 1.89B 28.43M 192M 74.89M 933M 73.93M 72.32M 3.23B | 53.91M 38.26M 33.62M 31.38M 28.8M 3.66B 55.24M 372M 146M 1.81B 144M 141M 6.27B |
| Net income | -25.75M -18.27M -16.06M -14.99M -13.75M -1.75B -26.38M -178M -69.5M -866M -68.6M -67.11M -2.99B | -27.81M -19.74M -17.34M -16.19M -14.86M -1.89B -28.49M -192M -75.06M -935M -74.1M -72.49M -3.23B |
| Net Debt | 38.94M 27.64M 24.28M 22.67M 20.8M 2.65B 39.9M 269M 105M 1.31B 104M 102M 4.53B | 58.26M 41.35M 36.33M 33.91M 31.12M 3.96B 59.7M 402M 157M 1.96B 155M 152M 6.77B |
Employees
70
Sector
Pharmaceuticals
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VPHIF Stock
Select your edition
All financial news and data tailored to specific country editions
